Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Mawson Infrastructure Group Inc. | ophthalix_ex9901.htm |
United States
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) December 30, 2013
OphthaliX Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-52545 | 88-0445169 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 10 Bareket Street, Petach Tikva, Israel | 4951778 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: +(972) 3-9241114
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 8.01 Other Events.
On December 30, 2013, OphthaliX Inc. issued a press release announcing the results of its Phase III trial of CF101 for the treatment of dry eye syndrome. A copy of the press release is included with this report.
Item 9.01 Financial Statements and Exhibits.
99.1 Press Release, dated December 30, 2013.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OphthaliX Inc. | ||
| Date: December 30, 2013 | By: | /s/ Barak Singer |
| Barak Singer, Chief Executive Officer | ||